Dr. Tripathy Discusses Iniparib Trial Heterogeneity

Debu Tripathy, MD
Published: Tuesday, Oct 11, 2011

Debu Tripathy, MD, professor of medicine and co-leader of the Women’s Cancer Program at the University of Southern California Norris Comprehensive Cancer Center, discusses the differences in survival among studies on iniparib in as a first-, second-, and third-line treatment.

The phase II trial showed a marked difference in survival and disease-free survival, but subsequent studies did not show that with first-line patients. In second- and third-line patients, however, the treatment was effective.

The differences in the trial results have led to discussions regarding tumor heterogeneity and how that heterogeneity might affect a population of patients rather than one particular tumor. In this case, the first-line patients might be different than the second- and third-line patients when it comes to their tumors. Tissue samples are being studied to determine what might be causing this heterogeneity.

Debu Tripathy, MD, professor of medicine and co-leader of the Women’s Cancer Program at the University of Southern California Norris Comprehensive Cancer Center, discusses the differences in survival among studies on iniparib in as a first-, second-, and third-line treatment.

The phase II trial showed a marked difference in survival and disease-free survival, but subsequent studies did not show that with first-line patients. In second- and third-line patients, however, the treatment was effective.

The differences in the trial results have led to discussions regarding tumor heterogeneity and how that heterogeneity might affect a population of patients rather than one particular tumor. In this case, the first-line patients might be different than the second- and third-line patients when it comes to their tumors. Tissue samples are being studied to determine what might be causing this heterogeneity.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication
x